Pfizer, breast cancer and Arvinas
Novo Nordisk announced disappointing data from a phase III study on a novel obesity candidate, CagriSema. Roche announced a ...
VERITAC-2 achieved its primary endpoint in the estrogen receptor 1-mutant population, demonstrating statistically significant and clinically ...
Trial results show vepdegestrant, a protein-degrading drug Arvinas is developing with Pfizer, improved on fulvestrant in a ...
Arvinas and Pfizer's drug vepdegestrant reduced the risk of tumor progression 40% compared to standard treatment for an ...
Morgan Stanley lowered the firm’s price target on Arvinas (ARVN) to $12 from $48 and keeps an Equal Weight rating on the shares after the ...
Topline results from the Phase III VERITAC-2 trial found that vepdegestrant provided a statistically significant and clinically meaningful improvement in progression-free survival in patients with ER+ ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results